Browse by author
Lookup NU author(s): Professor Andrew GenneryORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© The Author(s) 2025. Purpose: Patients with (X-linked) agammaglobulinemia (XLA) suffer from severe, recurrent infections potentially leading to life-threatening complications such as sepsis, meningoencephalitis and chronic lung disease. Early diagnosis and timely treatment can prevent infections and secondary complications, emphasizing a role for early detection of XLA via newborn screening (NBS). Our international multicenter survey study aimed to evaluate self-reported outcomes and parental perspectives in XLA patients to determine whether an early diagnosis is associated with better quality of life (QoL). Methods: QoL-questionnaires included the PedsQL for children and SF-36, CVID_QOL, PADQOL-16 for adults. A new questionnaire was specifically developed for parents about an early diagnosis of XLA. Results: In total, 88 adult and 65 pediatric XLA patients, and 69 parents from 14 countries completed the survey. Patients with an early diagnosis reported less severe, recurrent infections and less hospitalization (p < 0.05). QoL was significantly lower in multiple health domains for pediatric and adult patients with a late diagnosis compared to the general population. Patients with an early diagnosis reported similar QoL outcomes compared to the general population. Parents showed immense support for NBS for XLA stating that an early diagnosis prevents emotional insecurity, health damage, unnecessary diagnostics and allows early access to medical care and informed family planning. Conclusion: Our study has shown supportive evidence to pursue an early diagnosis of XLA from both a self-reported clinical, health related QoL and parental perspective. The main plea from patients and parents is to achieve an early diagnosis for XLA and severe B-lymphocyte deficiencies with NBS.
Author(s): Blom M, Duintjer AJ, Jamee M, de Gier M, Bloomfield M, Klocperk A, Kralickova P, Karaca NE, Boyarchuk O, Ciznar P, Jesenak M, Sharapova S, Skopovets E, Gonzalez-Granado LI, Palmeri S, Volpi S, Nalda AM, Tello SR, Soler-Palacín P, Abolhassani H, Pulvirenti F, Cinicola B, Wintergerst U, de Bree GJ, van den Berg JM, Leavis HL, Vermont C, Dalm VASH, van Aerde K, Henriet S, Jolink H, Potjewijd J, Lankester A, Mukherjee CR, Berghuis D, Pac M, Shillitoe BMJ, Gennery AR, van der Burg M
Publication type: Article
Publication status: Published
Journal: Journal of Clinical Immunology
Year: 2025
Volume: 45
Print publication date: 01/12/2025
Online publication date: 25/08/2025
Acceptance date: 16/06/2025
Date deposited: 09/09/2025
ISSN (print): 0271-9142
ISSN (electronic): 1573-2592
Publisher: Springer Nature
URL: https://doi.org/10.1007/s10875-025-01904-z
DOI: 10.1007/s10875-025-01904-z
Data Access Statement: Data is provided within the manuscript or supplementary information files. The raw datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
Altmetrics provided by Altmetric
